Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Axsome Therapeutics Inc(AXSM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AXSM
10/28/2026: AXSM (3-star) is currently NOT-A-BUY. Pass it for now.
Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing innovative treatments for CNS conditions like depression and sleep disorders. The company’s primary strength lies in its portfolio of approved, proprietary drugs, Auvelity and Sunosi, which provide a foundation of recurring revenue. Its investment story centers on expanding these brands while advancing a promising late-stage pipeline. However, Axsome faces intense competition from larger pharmaceutical firms and ongoing execution risks related to product commercialization and clinical development. The stock may best suit growth-oriented investors comfortable with high volatility, and market participants should monitor clinical data readouts and quarterly sales performance as key indicators of success.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is a rapidly growing commercial-stage biotech with significant upside potential tied to product adoption. |
| Momentum investor | Strong fit while signal remains positive | The stock often reacts strongly to clinical data readouts and commercial sales performance, favoring those monitoring trend signals. |
| Value investor | Weak fit | The company is currently focused on growth and lacks the profitability or dividends typical of value investments. |
| Dividend investor | Weak fit | Axsome does not pay a dividend and is not suitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Biotechnology stocks are inherently volatile and subject to high clinical and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on clinical results and market sentiment. |
| Valuation risk | Medium / high | Market expectations for rapid growth can lead to valuation premiums that are sensitive to any missed projections. |
| Competition risk (CNS market competition) | High | The company competes against much larger, well-capitalized firms in the CNS space. |
| Business quality | Medium | While the company has successfully launched products, it is still transitioning to sustained profitability. |
| Dividend income | Low / none | There is no dividend policy, making it unsuitable for income investors. |
| Execution risk | High | Success depends on ongoing commercial adoption and the achievement of further clinical pipeline milestones. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 58.47% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 7.45B USD | Price to earnings Ratio - | 1Y Target Price 279.38 |
Price to earnings Ratio - | 1Y Target Price 279.38 | ||
Volume (30-day avg) 875.0K shares | Beta 0.85 | 52 Weeks Range 123.50 - 260.19 | Updated Date 10/28/2026 |
52 Weeks Range 123.50 - 260.19 | Updated Date 10/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.74 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Products | Revenue generated from the sale of Auvelity and Sunosi in the United States. | The company primarily makes money by selling prescription drugs used to treat CNS disorders like depression and sleep disorders. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 23.92 | Enterprise Value 7.45B | Price to Sales(TTM) 9.59 |
Enterprise Value 7.45B | Price to Sales(TTM) 9.59 | ||
Enterprise Value to Revenue 9.59 | Enterprise Value to EBITDA -14.81 | Shares Outstanding 52.38M | Shares Floating 44.46M |
Shares Outstanding 52.38M | Shares Floating 44.46M | ||
Percent Insiders 15.08 | Percent Institutions 74.39 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.